HIV antibody duds explained

Researchers may have finally answered the question of why many antibodies that target the HIV envelope are still unable to stop the virus from spreading -- a troublesome stumbling block in the protracted search for an effective vaccine. Human Immunodeficiency VirusImage: Wikimedia commons, NIAIDSlight variations in how those antibodies interact with their target on the HIV envelope cause conformational changes in the target molecule that render the antibodies ineffective, according to a study p

Written byJef Akst

| 3 min read

Save for Later

Human Immunodeficiency Virus
Image: Wikimedia commons,
NIAID

Slight variations in how those antibodies interact with their target on the HIV envelope cause conformational changes in the target molecule that render the antibodies ineffective, according to a study published this week in Science. This research "helps us to understand the molecular level details of [how certain antibodies bind] with better clarity than before," said viral immunologist linkurl:David Montefiore;http://humanvaccine.duke.edu/modules/montefiori/index.php?id=1 of Duke University, who was not involved in the work. "Understanding the atomic level [detail] that they [describe] here is very helpful for designing immunogens to elicit the right kinds of antibodies we want vaccines to elicit." In the hunt for an effective HIV vaccine, one promising target site is the CD4 binding site on the HIV-1 envelope. The virus uses this binding site, called a viral spike, to enter the CD4 immune cells it infects. In theory, antibodies that bind to and block this site could protect cells from infection. In practice, however, several antibodies identified from HIV-infected individuals do target the viral spike, but for unknown reasons, most of those antibodies cannot bind and therefore fail to stop the virus's spread. Only one -- the b12 antibody -- appears effective, neutralizing about half of circulating viruses. In circulating HIV, the viral spike includes three gp120 glycoproteins in a trimer formation. Only b12 can bind gp120 as a trimer, but once each gp120 is isolated from the trimer formation, even the ineffective antibodies can bind to it. Theoretically, vaccine efforts could target b12, but the gp120 trimer is not stable enough to be used as an immunogen in a vaccine. As a result, vaccine efforts targeting b12 mostly use the gp120 monomer, which unfortunately elicits a variety of antibodies that target it, most of which are ineffective. To determine why only b12 can bind to gp120 in its natural form, linkurl:Peter Kwong,;http://www.the-scientist.com/article/display/54324/ a structural biologist at the Vaccine Research Center of the National Institutes of Health, and his colleagues performed x-ray crystallography on two ineffective antibodies bound to the gp120 monomer -- F105 and b13. They then compared the atomic details of these antibody-gp120 complexes with the details of the b12-gp120 complex. As predicted, all three antibodies bound to very similar locations on the gp120 glycoprotein, but very slight differences in binding -- on the order of a few angstroms -- caused dramatically different conformational changes between the envelope protein bound to b12 and the proteins bound to other antibodies. The researchers used computer models to reconstruct what these changed gp120 glycoproteins might look like in trimer form and found that those bound to the ineffective antibodies didn't fit -- the new conformations were incompatible with a functional viral spike. These conformational changes, the authors suggest, may explain why the ineffective antibodies fail to bind altogether, thereby failing to neutralize the virus. Kwong suggested that eliciting such ineffective antibodies may be HIV's way of activating the host immune system -- which it needs to do in order to spread -- without causing a response that will hurt it. It's "part of the whole decoy system HIV uses to turn on the immune system, [but] not in a manner that it could effectively neutralize the virus," he said. To create an effective vaccine, then, scientists must figure out a way to elicit antibodies that precisely target the viral spike in a way that does not induce these incompatible conformational changes. The existence of b12, a moderately effective antibody, is nature's proof that "it's possible," Montefiore said, "but we just haven't figured out how to do it yet." One way to force the immune response to precisely target the viral spike may be to play with the glycans that coat the viral spike of a potential vaccine immunogen, Kwong said. Locations with glycans are ignored by the immune system. By trimming back the glycans surrounding the exact site of ideal antibody binding and adding glycans to other parts that should be avoided, researchers could potentially direct the immune system to generate only those antibodies that would be most effective against HIV. "We don't have a vaccine yet," Kwong said. "[But] this knowledge provides an explanation of what's going on, [and is] another important step in the process of obtaining the vaccine."
**__Related stories:__***linkurl:Modest HIV protection confirmed;http://www.the-scientist.com/blog/display/56067/
[20th October 2009]*linkurl:Hubbub brews for HIV vax data;http://www.the-scientist.com/blog/display/56052/
[12th October 2009]*linkurl:New wrinkle for HIV vaccine;http://www.the-scientist.com/blog/display/55478/
[25th February 2009]

Meet the Author

Jef Akst

Jef (an unusual nickname for Jennifer) got her master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses. After four years of diving off the Gulf Coast of Tampa and performing behavioral experiments at the Tennessee Aquarium in Chattanooga, she left research to pursue a career in science writing. As The Scientist's managing editor, Jef edited features and oversaw the production of the TS Digest and quarterly print magazine. In 2022, her feature on uterus transplantation earned first place in the trade category of the Awards for Excellence in Health Care Journalism. She is a member of the National Association of Science Writers.

View Full Profile

HIV antibody duds explained

The Scientist ARCHIVES

Become a Member of

Meet the Author

Jef Akst

Related Research Resources

What Is the Amniotic Fluid Composed of?

Research Resources

Podcasts

Webinars

Videos

Infographics

eBooks

Advancing Drug Discovery with Complex Human In Vitro Models

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Skip the Wait for Protein Stability Data with Aunty

Products

Product News

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies

Parse Biosciences and Graph Therapeutics Partner to Build Large Functional Immune Perturbation Atlas

Sino Biological's Launch of SwiftFluo® TR-FRET Kits Pioneers a New Era in High-Throughout Kinase Inhibitor Screening

SPT Labtech enables automated Twist Bioscience NGS library preparation workflows on SPT's firefly platform